VRTX

Vertex Pharmaceuticals Stock Price

188.00
-0.87 (-0.46%)
188.00

Low
185.325

52 Week Range

High
306.08

Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Vertex Pharmaceuticals Inc VRTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.87 -0.46% 188.00 17:53:10
Open Price Low Price High Price Close Price Prev Close
188.19 187.09 189.78 187.52 188.87
Bid Price Ask Price Spread News
187.30 187.70 0.40 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
28,456 1,930,514 $ 187.94 $ 362,827,114 2,368,454 185.325 - 306.08
Last Trade Time Type Quantity Stock Price Currency
17:57:31 1 $ 187.65 USD

Vertex Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 48.67B 258.87M 258.72M $ 6.21B $ 2.67B 10.31 17.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 14.29k 0.90%

more financials information »

Vertex Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical VRTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week189.37192.55185.325188.042,897,306-1.37-0.72%
1 Month209.63217.26185.325197.812,963,320-21.63-10.32%
3 Months213.38222.78185.325206.681,989,012-25.38-11.89%
6 Months235.40242.99185.325213.471,990,325-47.40-20.14%
1 Year294.06306.08185.325228.491,845,953-106.06-36.07%
3 Years158.72306.08145.37213.091,553,59029.2818.45%
5 Years86.21306.0871.46176.931,582,249101.79118.07%

Vertex Pharmaceuticals Description

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex's pipeline includes gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease as well as small-molecule medicines targeting diseases associated with alpha-1 antitrypsin deficiency and APOL1-mediated kidney disease. Vertex also has an expanding research pipeline focused on inflammatory diseases, non-opioid treatments for pain, and genetic and cell therapies for type 1 diabetes and rare diseases.


Your Recent History
NASDAQ
VRTX
Vertex Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.